Evidence map›Paper›PMID 28094136›Full record

Trial reportThe lancet. Diabetes & endocrinology2017

Day-and-night glycaemic control with closed-loop insulin delivery versus conventional insulin pump therapy in free-living adults with well controlled type 1 diabetes: an open-label, randomised, crossover study.

Lia Bally, Hood Thabit, Harald Kojzar, Julia K Mader, Jehona Qerimi-Hyseni, Sara Hartnell, Martin Tauschmann, Janet M Allen, Malgorzata E Wilinska, Thomas R Pieber and 2 more

Registry-linked trialOpen access · hybridAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in The lancet. Diabetes & endocrinology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06466967 (Clinical Utility of a Tight Glucose Objectives Through Advanced Hybrid Closed-loop Systems in Adult Patients With Type 1 Diabetes and Poor Glycemic Control), which is not on this map. Cited by 58 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
58citing papers in PubMed, 5 pooled it
12.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06466967 completednot on this mapstarted 2024, after this paper: background citation

Clinical Utility of a Tight Glucose Objectives Through Advanced Hybrid Closed-loop Systems in Adult Patients With Type 1 Diabetes and Poor Glycemic Control

Typeobservational_patient_registrySponsorCastilla-La Mancha Health ServiceRan2024 to 2026Enrolled40ConditionsType 1 DiabetesArmsAdvanced hybrid closed-loop CamAPS FX
3 · Its place in the literature

Who cites it

58 citing papers in PubMed, 5 syntheses or guidelines pooled it, 145 citations in OpenAlex.

  1. Pooled it
  2. Real-World Evidence of Automated Insulin Delivery System Use.Diabetes technology & therapeutics · 2024
    Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Bolusing frequency and amount impacts glucose control during hybrid closed-loop.Diabetic medicine : a journal of the British Diabetic Association · 2018
    Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 3 countries.

Lia BallyWellcome Trust-Medical Research Council Institute of Metabolic Science, University of Cambridge, Cambridge, UK; Department of Diabetes & Endocrinology, Cambridge University Hospitals National Health Service Foundation Trust, Cambridge, UK; Department of Diabetes, Endocrinology, Clinical Nutrition & Metabolism, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
Hood ThabitWellcome Trust-Medical Research Council Institute of Metabolic Science, University of Cambridge, Cambridge, UK; Department of Diabetes & Endocrinology, Cambridge University Hospitals National Health Service Foundation Trust, Cambridge, UK.
Harald KojzarDepartment of Internal Medicine, Division of Endocrinology & Diabetology, Medical University of Graz, Graz, Austria.
Julia K MaderDepartment of Internal Medicine, Division of Endocrinology & Diabetology, Medical University of Graz, Graz, Austria.
Jehona Qerimi-HyseniDepartment of Internal Medicine, Division of Endocrinology & Diabetology, Medical University of Graz, Graz, Austria.
Sara HartnellDepartment of Diabetes & Endocrinology, Cambridge University Hospitals National Health Service Foundation Trust, Cambridge, UK.
Martin TauschmannWellcome Trust-Medical Research Council Institute of Metabolic Science, University of Cambridge, Cambridge, UK; Department of Paediatrics, University of Cambridge, Cambridge, UK.
Janet M AllenWellcome Trust-Medical Research Council Institute of Metabolic Science, University of Cambridge, Cambridge, UK; Department of Paediatrics, University of Cambridge, Cambridge, UK.
Malgorzata E WilinskaWellcome Trust-Medical Research Council Institute of Metabolic Science, University of Cambridge, Cambridge, UK; Department of Paediatrics, University of Cambridge, Cambridge, UK.
Thomas R PieberDepartment of Internal Medicine, Division of Endocrinology & Diabetology, Medical University of Graz, Graz, Austria.
Mark L EvansWellcome Trust-Medical Research Council Institute of Metabolic Science, University of Cambridge, Cambridge, UK; Department of Diabetes & Endocrinology, Cambridge University Hospitals National Health Service Foundation Trust, Cambridge, UK.
Roman HovorkaWellcome Trust-Medical Research Council Institute of Metabolic Science, University of Cambridge, Cambridge, UK; Department of Paediatrics, University of Cambridge, Cambridge, UK. Electronic address: rh347@cam.ac.uk.
Medical University of Graz · ATMedical Research Council · GBWellcome/MRC Institute of Metabolic Science · GBCambridge University Hospitals NHS Foundation Trust · GBUniversity Hospital of Bern · CH

Funding

Wellcome Trust
6 · The paper itself

Abstract

backgroundTight control of blood glucose concentration in people with type 1 diabetes predisposes to hypoglycaemia. We aimed to investigate whether day-and-night hybrid closed-loop insulin delivery can improve glucose control while alleviating the risk of hypoglycaemia in adults with HbA

methodsIn this open-label, randomised, crossover study, we recruited adults (aged ≥18 years) with type 1 diabetes and HbA

findingsBetween March 21 and June 24, 2016, we recruited 31 participants, of whom 29 were randomised. One participant withdrew during the first closed-loop period because of dissatisfaction with study devices and glucose control. The proportion of time when sensor glucose concentration was in target range was 10·5 percentage points higher (95% CI 7·6-13·4; p<0·0001) during closed-loop delivery compared with usual pump therapy (65·6% [SD 8·1] when participants used usual pump therapy vs 76·2% [6·4] when they used closed-loop). Compared with usual pump therapy, closed-loop delivery also reduced the proportion of time spent in hypoglycaemia: the proportion of time with glucose concentration below 3·5 mmol/L was reduced by 65% (53-74, p<0·0001) and below 2·8 mmol/L by 76% (59-86, p<0·0001). No episodes of serious hypoglycaemia or other serious adverse events occurred.

interpretationUse of day-and-night hybrid closed-loop insulin delivery under unsupervised, free-living conditions for 4 weeks in adults with type 1 diabetes and HbA

fundingSwiss National Science Foundation (P1BEP3_165297), JDRF, UK National Institute for Health Research Cambridge Biomedical Research Centre, and Wellcome Strategic Award (100574/Z/12/Z).

Indexed as

Infusion Pumps, ImplantableInsulin Infusion SystemsAdultCross-Over StudiesDiabetes Mellitus, Type 1FemaleHumansHypoglycemiaHypoglycemic AgentsInsulinMaleMiddle AgedTime FactorsTreatment OutcomeHypoglycemic AgentsInsulin

Identifiers

PMID28094136
PMCPMC5379244
OpenAlexW2579875664

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.